The first program to utilise Alnylam's proprietary C16-siRNA technology was ALN-APP (NCT05231785),17 in collaboration with Regeneron, designed to target amyloid precursor protein (APP) for the potential treatment of Alzheimer's disease (AD) and cerebral amyloid angiopathy (CAA). The gene discussed is APP; the disease is Alzheimer disease.